Pepsinogens as the Early Marker of H. Pylori Eradication

Status Completed

Clinical Trial Summary

Helicobacter pylori (H. pylori) eradication increases the serum pepsinogen (PG) I/PG II ratio and the percentage change in PG I/PG II ratios was found to be a useful marker of H. pylori eradication (e.g., the PG method). We studied whether the PG method could be an early diagnostic marker of H. pylori eradication even in patients persistently treated with a proton pump inhibitor. Sixty-two H. pylori-positive patients underwent H. pylori-eradication therapy, followed by treatment with a PPI to cure ulcers. Serum levels of PG I and PG II were measured before, at the end of, and at 4 weeks after the eradication therapy. At more than one month after the end of treatments, 13C-urea breath test (UBT) was performed. The cut-off values of percentage changes in PG I/PG II ratios for the diagnosis of eradication of H. pylori were set in proportion to PG I/PG II ratios before eradication in accordance with our previous report. Using the results of UBT as the standard, the percentage change in serum PG I/PG II ratios is useful as an early diagnostic marker for judgment of H. pylori eradication irrespective of PPI treatment.

Clinical Trial Description

n/a

Study Design

Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00197457
Study type	Interventional
Source	Hamamatsu University
Contact
Status	Completed
Phase	Phase 2
Start date	June 2001

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT05518929` - Hypoxia During Gastroenterological Endoscope Procedures Sedated With Ciprofol In Overweight Or Obesity Patients	Phase 4
Completed	`NCT03291418` - To Compare the Gastrointestinal Safety of a 14-Day Oral Dosing Regimen of ATB-346 to Sodium Naproxen in Healthy Subjects	Phase 1/Phase 2
Not yet recruiting	`NCT05526339` - HFNO Combined With NPA Reduces Hypoxia During Sedated Gastrointestinal Endoscopy In Obese Patients	N/A
Completed	`NCT01435525` - Nexium Capsules Helicobacter Pylori Specific Clinical Experience Investigation	N/A
Terminated	`NCT00594854` - Evaluating PN 400 (VIMOVO) in Reducing Gastric Ulcers in High Risk Subjects Compared to Arthrotec	Phase 3
Completed	`NCT00527787` - Evaluating PN 400 (VIMOVO) in Reducing Gastric Ulcers Compared to Non-steroidal Antiinflammatory Drug (NSAID) Naproxen	Phase 3
Completed	`NCT01129011` - Evaluating PN 400 (VIMOVO) in Reducing Gastric Ulcers Compared to Non-steroidal Antiinflammatory Drug (NSAID) Naproxen	Phase 3
Recruiting	`NCT05517408` - Dose Exploration of Ciprofol for Sedation in Gastrointestinal Endoscopic Diagnosis and Treatment of Obese Patients.	N/A
Recruiting	`NCT01946633` - Remote-controlled Capsule Endoscopy: a Feasibility Study	N/A
Completed	`NCT01964131` - BE Study Between a Capsule and a Sachet Formulation of D961H by Pharmacodynamics in Japanese Healthy Male Subjects	Phase 1
Completed	`NCT01150162` - Mucosta in Gastric Ulcer Treatment, Effectiveness and Safety Evaluation	Phase 3
Recruiting	`NCT01037491` - Comparison of Ulcer Healing in Patients Taking Rabeprazole With Different Antiplatelets	N/A
Completed	`NCT00960869` - Study to Evaluate the Incidence of Gastric Ulcers Following Administration of Either PA32540 or Enteric Coated Aspirin 325 mg in Subjects Who Are at Risk for Developing Aspirin-Associated Ulcers	Phase 3
Completed	`NCT00961350` - A Study to Evaluate the Incidence of Gastric Ulcers Following Administration of Either PA32540 or Enteric Coated Aspirin 325 mg in Subjects Who Are at Risk for Developing Aspirin-Associated Ulcers	Phase 3
Completed	`NCT00595517` - Long Term Study to Investigate the Efficacy & Safety of D961H (Esomeprazole) for the Prevention of NSAIDs-induced Ulcer	Phase 3
Completed	`NCT00428701` - An Open-label, Exploratory Trial to Assess Gastric Acid Control in Critically Ill Subjects Receiving Nexium	Phase 4
Completed	`NCT01452711` - Efficacy of TAK-438 Compared to AG-1749 (Lansoprazole) in the Treatment of Gastric Ulcer	Phase 3
Terminated	`NCT05579444` - Systems Biology of Gastrointestinal and Related Diseases
Completed	`NCT02761512` - Study to Evaluate the Safety and Efficacy of CJ-12420 in Patients With Gastric Ulcer	Phase 3
Recruiting	`NCT03057171` - A Study on the Gastrointestinal Disease and Helicobacter Pylori Controlled Long Non-coding RNA